Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Charlene Mantia, M.D.

Concepts (70)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Intracranial Hemorrhages320198290.980 Why?
Carcinoma, Transitional Cell220227530.710 Why?
Urologic Neoplasms120223080.670 Why?
Venous Thromboembolism3201915820.640 Why?
Urinary Bladder Neoplasms3202220760.560 Why?
Immunoconjugates120228290.550 Why?
Carcinoma, Renal Cell5202129520.550 Why?
Enoxaparin120173640.530 Why?
Anticoagulants3201943750.510 Why?
Immunotherapy3202040880.500 Why?
Kidney Neoplasms5202140150.490 Why?
Brain Neoplasms3201988010.340 Why?
Melanoma2202252460.310 Why?
Adenocarcinoma1202163200.230 Why?
Skin Neoplasms1202253190.230 Why?
Glioma1201733050.220 Why?
Vinblastine120215070.180 Why?
5'-Nucleotidase120201590.180 Why?
Administration, Cutaneous120217040.170 Why?
Prostatic Neoplasms12021105950.170 Why?
Dermatitis120191930.160 Why?
Deoxycytidine120218270.150 Why?
Heparin, Low-Molecular-Weight120183260.150 Why?
Antineoplastic Agents12019136190.140 Why?
Small Cell Lung Carcinoma120193530.140 Why?
Cisplatin1202116440.130 Why?
Doxorubicin1202122180.130 Why?
Methotrexate1202117260.130 Why?
Estrogens1202115290.120 Why?
Androgens1202112310.120 Why?
Estradiol1202119820.120 Why?
Survival Analysis22022105130.110 Why?
Antineoplastic Combined Chemotherapy Protocols32021112380.100 Why?
Neoadjuvant Therapy1202125550.100 Why?
Neoplasms12019205150.100 Why?
Vascular Endothelial Growth Factor A1201934910.080 Why?
Humans1620227155940.080 Why?
Double-Blind Method12022119480.080 Why?
Neoplasm Proteins1201937380.070 Why?
Kaplan-Meier Estimate1201767270.070 Why?
Antibodies, Monoclonal1202295440.070 Why?
Male920223501430.060 Why?
Delivery of Health Care1202148840.060 Why?
Aged, 80 and over42020582930.050 Why?
Retrospective Studies52021724480.050 Why?
Female920223770520.050 Why?
GPI-Linked Proteins120204410.050 Why?
Retreatment120206230.040 Why?
Class I Phosphatidylinositol 3-Kinases120228990.040 Why?
Aged520211623920.040 Why?
Middle Aged620212146390.040 Why?
Lung Neoplasms12019125300.030 Why?
Young Adult22020561400.030 Why?
Adult520212122370.030 Why?
Cohort Studies12017400400.030 Why?
Risk Factors22018709310.030 Why?
Salvage Therapy1202013070.030 Why?
Administration, Oral1201839510.020 Why?
High-Throughput Nucleotide Sequencing1202236700.020 Why?
Neoplasm Staging12019111390.020 Why?
Gene Expression Profiling1202094940.020 Why?
Disease Progression12020132190.010 Why?
Treatment Outcome22019620390.010 Why?
Incidence12018207610.010 Why?
Prognosis12020289910.010 Why?
Follow-Up Studies12021393340.010 Why?
Mutation12022292530.010 Why?
Prospective Studies12021513540.010 Why?
Risk Assessment12018234820.010 Why?
Time Factors12018408890.010 Why?
Mantia's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (70)
Co-Authors (28)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.